esthinylestradiol

PreclinicalSmall molecule

UUniversity Hospital, Basel, Switzerland

esthinylestradiol is one of 2 small molecule programs targeting AVP Deficiency. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AVP DeficiencyRecruiting

AVP DeficiencyPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in AVP Deficiency

#DrugCompanyPhaseTrials

Estrasorb

Novo Nordisk

Preclinical

1 2

esthinylestradiol

UUniversity Hospital, Basel, Switzerland

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

AVP Deficiency

NCT07361263

Clinical

Trials by Indication[1]

AVP Deficiency1 trial

Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol in Healthy Controls and Patients With AVP-Deficiency

Recruiting·UUniversity Hospital, Basel, Switzerland·Preclinical·NCT07361263·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for esthinylestradiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — esthinylestradiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for esthinylestradiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Basel, Switzerland

esthinylestradiol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

AVP Deficiency1 trial

References

Drug Info

Quick Facts

Related News